


# Customer Spotlight

## For Single Cell Discoveries, the single most vital tool for scalability is automation



**Oriol Llorà-Batlle**  
Team Lead, R&D, Single Cell Discoveries

Scalability in single-cell transcriptomics is now imperative for meeting a growing demand for higher throughput.

Over the past decade, the single-cell transcriptomics field has undergone a significant transformation, with major advancements in efficiency, modalities and accessibility.

Today, single-cell transcriptomics spans a wide range of fields and applications, and as this field grows, scalability has become crucial to meet increasing throughput demands.

For **Single Cell Discoveries (SCD) in Utrecht**, a key tool for achieving efficient scalability has always been workflow automation.

“Automation and liquid handlers have been integral to our single-cell pipeline since its inception,” says Oriol Llorà-Batlle, Team Lead for Research & Development at SCD.

“We strive to match the right technology and analysis to address all types of biological questions. Relying on state-of-the-art automation tools has enabled us to provide some of the fastest turnaround times in the industry—less than four weeks for single-cell experiments and just two weeks for sequencing.”

### About Single Cell Discoveries BV

A leading single-cell sequencing Contract Research Organization (CRO), Single Cell Discoveries (SCD) is focused on providing cutting-edge single-cell sequencing services to biopharmaceutical companies, health systems, and academic research centers globally. Located in Utrecht, the Netherlands, their team of PhD scientists is dedicated to developing customized solutions for unique scientific questions, all while ensuring rapid turnaround times and high quality.

To address the escalating needs of the single-cell transcriptomics field, SCD depends on a **Biomek i7 Hybrid Automated Workstation** and the **SPRIselect bead-based reagent** to perform their library preparations.

“Leveraging our expertise, we have also served as testers for the new 10x-validated automated library preparation solution for their Chromium Universal 3' and 5' scRNA-seq kits.”

To be sure, partnerships with companies such as Beckman Coulter Life Sciences and 10x Genomics have helped SCD to rapidly scale up its global leadership position among CROs. Their reputation for high-touch, client-focused engagement is evidenced by how closely they work with customers and partners to achieve objectives for all

“Key partnerships have always played a dual role in our operations,” says Llorà-Batlle.

“In alignment with our company’s mission and vision, we work with our partners and customers on projects that help adapt single-cell applications to numerous purposes. Meanwhile, we enjoy mutual access to resources and experience that fuel our own evolution.”

### Discovery-seq for high-throughput RNA sequencing


One of the many services SCD provides is called Discovery-seq, which entails high-throughput RNA sequencing of hundreds of samples in 384-well plates. This in-house-developed method was based on SCD’s single-cell and bulk RNA-seq technologies—and is compatible with cell lines and organoids.

Among the advantages of Discovery-seq is its ability to obtain RNA sequencing data from thousands of samples via a single experiment, and to analyze the effects of a variety of perturbations. SCD’s automated protocols—including use of a **Biomek i7 Automated Workstation, Echo 525 Acoustic Liquid Handler and RNAClean XP reagent kits**—helps the company provide quick turnaround times while optimizing cost-efficiency for each experiment.

After each experiment, SCD’s bioinformaticians can also assist with uncovering important insights through custom data analysis.

### SCD continues scaling up for even more success

The midpoint of this decade has seen significant growth for Single Cell Discoveries.



Among the many technologies on which SCD relies are the Biomek i7 hybrid workstation (shown above), an Echo (525) Access Workstation, and SPRI bead-based reagents including AMPure XP and RNAClean XP kits.

As demand continues to increase for rapid turnaround times, an end-to-end approach, and high-quality transcriptomics, SCD is strategically expanding its team of experts, enhancing their R&D programs, and scaling their operations to meet the ever-growing needs of the scientific community worldwide.

“We aim to provide tailored solutions for any biological question,” explains Llorà-Batlle.

“And we’re committed to offering a comprehensive range of services to support researchers in addressing even the most complex scientific challenges with unparalleled precision, and at an accelerated pace made possible thanks to automation.”

For more information about SCD, visit [scdiscoveries.com](https://scdiscoveries.com)

For more information about 10x Genomics GEM-X Universal assays, visit [10xgen.com/Universal](https://10xgen.com/Universal)

For information about Biomek Automated Workstations, Echo Acoustic Liquid Handlers and SPRI-based reagents, visit [beckman.com](https://beckman.com)



Products are not intended or validated for use in diagnostic procedures.

© 2025 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. ECHO is a trademark or registered trademark of Labcyte Inc. in the United States and other countries. Labcyte is a Beckman Coulter company. All other trademarks are the property of their respective owners.

For Beckman Coulter’s worldwide office locations and phone numbers, please visit Contact Us at [beckman.com](https://beckman.com)  
2025-GBL-EN-108756-v2

